[12] Patent
[11] Patent No.:GC0010748  
[45] Date of Publishing the Grant of the Patent: 31/Oct /2019                63/2019  
Number of the Decision to Grant the Patent:2019/156866
Date of the Decision to Grant the Patent:10/Sep/2019

[21] Application No.:GC 2013-25720

[22] Filing Date:4/11/2013

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
16/7/2013
13/943,634

[72] Inventors:1- HITCHCOCK,Steve،2- MONENSCHEIN, Holger،3- REICHARD, Holly،4- SUN, Huikai،5- KIKUCHI, Shota،6- MACKLIN, Todd،7- HOPKINS, Maria

[73] Owner: TAKEDA PHARMACEUTICAL COMPANY LIMITED, 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045, Japan

[74] Agent: Kadasa Law Firm

  

 

  

[51]IPC:
Int. Cl.: C07D 401/04, 401/12, 401/14 (2006.01)

[56] Cited Documents:

-US 2005/234095 A1 (XIE WENGE [US] ET AL) 20 October 2005
-WO 2009/108551 A2 (LUNDBECK & co AS H ; BAKTHAVATCHALAM RAJAGOPAL [US] ; I HLE DAVID c [US] ; ) 3 September 2009
-WO 2009/023623 A1 (NEUROGEN CORP [US];BAKTHAVATCHALAM RAJAGOPAL [US]; IHLE DAVID C [US];) 19 February 2009
-EP 0 469 449 A1 (NISSHIN FLOUR MILLING CO [JP]) 5 February 1992
-EP 0 200 444 A2 (BEECHAM GROUP PLC [GB]) 5 November 1986
-EP 0 708 105 A1 (NISSHIN FLOUR MILLING CO [JP]) 24 April 1996
 
Examiner: PH. Mohammad S. AlMousa

[54] 5-HT3 RECEPTOR ANTAGONISTS
[57] Abstract: The present invention provides 5-HT3 receptor antagonists of Formula (I):which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
No. of claims: 3


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.